Double Trouble: Linvatec Subsidiary Gives Conmed Regulatory Headache
This article was originally published in The Gray Sheet
Executive Summary
Conmed failed to adequately address thousands of medical device complaints, according to an FDA warning letter released July 26
You may also be interested in...
Conmed Joins Ethicon Marketing Critics; FTC, State AGs Probe Suture Sales
Johnson & Johnson's marketing practices preclude hospitals from bidding on Conmed endoscopy devices that cost nearly 30% less than comparable J&J items, the smaller company alleges
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.